drugset / Trial / NCT03236610

Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir

NCT03236610

Phase 3 Unknown 112 enrolled Uijeongbu St. Mary Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Little is known about efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic ehpatitis B patients who achieved a complete virological response to entecavir and tenofovir. This study aimed to investigate the efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic hepatitis B patients with undetectable heaptitis B virus DNA while on tenofovir plus entecavir combination therapy.

Timeline

Start
2016-01-01
Primary completion
2018-06-30
Completion
2019-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entecavir Small molecule
Subject Tenofovir Small molecule

Indications

No indication recorded.